Overview

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Status:
Completed

Trial end date:
2021-05-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate Long-term outcomes following treatment with ABT-450/r/ABT-267 and ABT-333 with or without RBV in adults with genotype 1 Chronic Hepatitis C Virus (HCV) infection.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Ribavirin
Ritonavir